---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012137"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:20:48.824613+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled

## Summary
- Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.
- Cash $27.9M at June 30, 2024; expects to fund operations into Q2 2025; closed $20M upfront financing with up to $50M milestone warrants.
- DA-1726 SAD Part 1 fully enrolled (45 patients); top-line data expected Q3 2024; MAD Part 2 top-line Q1 2025.
- DA-1241 MASH Phase 2a top-line results expected Q4 2024; pre-clinical combination data with semaglutide presented.
- Signed joint research agreement for once-monthly DA-1726 formulation; out-licensed NB-01 for painful diabetic neuropathy.

## SEC filing metadata
- accession: 0001558370-24-012137
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/0001558370-24-012137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024012137/nrbo-20240814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012137
- JSON: https://secwatch.observer/filing/0001558370-24-012137.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.